Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
More COVID-19 vaccines are beginning to flow into Africa, as coordination between partner organizations and African governmental agencies improves. However, gaps remain in cold chain storage, information flow on the ground is lagging and vaccine hesitancy persists. Also, pandemic-related economic depression in some African countries is jeopardizing procurement and access to vaccines.
Brazil has established an accelerated pathway for approval of drugs for ultra-rare diseases, encouraging development activity – but the definition of qualifying drugs is narrow. Expansion to include more treatments could boost clinical trials activity and companies’ overall development presence.
Shaped by Brexit, driven by COVID, squeezed by budgets and being engineered for the future, it seems that almost every element within UK health delivery and market access is undergoing change. How should the medtech industry prepare, and will there be implications beyond the UK?
Legal experts discuss the intricacies around pharma’s demand for indemnity, a key sticking point for supplies of COVID-19 vaccines from Pfizer and Moderna, and the path forward for countries like India.
The family-owned German pharma dates back to 1885 and tries to keep up with its publicly traded peers by not mimicking everything they do, but with a “value by innovation” focus.
Focus On Switzerland – Part 4: The fragile nature of start-ups belies their value in medtech innovation, and they do not need unnecessary regulatory complications.
Focus On Switzerland – Part 3: Robotics means different things to different surgeons, according to Swiss innovator Distalmotion, whose surgical robot combines with laparoscopy to leave the surgeon fully in control in the OR.
Focus On Switzerland – Part 2. Health warning to global medtechs: the world’s largest medtech company is taking steps to strengthen key account management, retain its market share hold and set up new health care partnerships.
Focus On Switzerland – Part 1: Switzerland is a high-tech microcosm of the medtech industry. It is home to the EMEA headquarters of the world’s largest medtech group, Medtronic, and supports a vibrant SME and start-up community, in the example of hybrid soft tissue robotics company Distalmotion. In Vivo interviewed both for this feature on the contribution of Swiss medtech in the advancement of patient care, domestically and globally.
South Korea is the tenth largest economy in the world with a population of 51.3 million. Alongside fast growth of the region’s technology-driven economy, its pharma industry has been expanding significantly too.
CEO Umang Vohra outlines where Cipla is heading in its priority areas of lung route therapies and antimicrobial resistance. He also weighs in on the simmering issue of intellectual property waivers for COVID-19 vaccines.
A COVID-19 second wave is wreaking havoc in India but pharma appears to be holding things together for now, stretching resources amid a dip in personnel attendance and supply chain strains. Limited vaccine supplies, a spurt in API prices and an inevitable third wave could mean further turbulence ahead.
Using PD-1 immuno-oncology drugs to treat post-surgery gastric cancer and prescribing unapproved targeted therapies for colon cancer are just two examples of the apparently widespread misuse of oncology drugs in China, as alleged by an oncologist at a prestigious Peking university hospital.
Senior McKinsey executive shares insights on the potential contours of pharma’s 'reimagined' operations against the backdrop of COVID-19 and striking a balance between supply chain security and the cost component. A dramatic near-term shift to a “completely onshore model” in markets like the US would not realistically be possible, he indicated.
After 45 years as a domestic Japanese biopharmaceutical company, JCR Pharmaceuticals is expanding into global markets. The company is betting that its manufacturing strength – which helped land a COVID-19 vaccine manufacturing deal with AstraZeneca – and blood-brain barrier crossing J-Brain Cargo technology will lead to success in Western markets.
Kazakhstan’s pharmaceutical market showed positive dynamics in 2020. In the first 9 months of last year, market size for finished pharmaceutical products grew to KZT460bn($1bn), up 22% year-on-year.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.